DGAP-News: Resinco Capital Partners Announces the Appointment of Sir Marc Feldmann to Advisory Board

Nachricht vom 06.02.201906.02.2019 (www.4investors.de) -

DGAP-News: Resinco Capital Partners Inc. / Key word(s): Miscellaneous

Resinco Capital Partners Announces the Appointment of Sir Marc Feldmann to Advisory Board
06.02.2019 / 06:01

The issuer is solely responsible for the content of this announcement.

Vancouver, British Columbia--(Newsfile Corp. - February 6, 2019) - Resinco Capital Partners Inc. (CSE: RIN) (OTC Pink: RSCZF) (FSE: L6V1) (the 'Company' or 'Resinco') is pleased to announce that the Company has appointed pioneer and trailblazer of modern immunology, Sir Marc Feldmann, to its Advisory Board after fully acquiring his company, ReFormation Pharmaceuticals Corp, a medical cannabis company developing innovative, first-in-class therapies to repair vital organs and stem cells by combining cannabinoids and an endogenous trigger of repair.Sir Marc Feldmann, whose research breakthrough on inflammation led to the creation of some of the world's top-selling drugs like Humira and Remicade, is embracing medical marijuana, through co-founding ReFormation Pharmaceuticals with Professor Jagdeep Nanchahal. Specifically, ReFormation Pharmaceuticals has identified a molecule (HMGB1) that primes the body's own stem cells to accelerate repair and regeneration following acute or chronic injury. 'As medical marijuana regulations ease, Feldmann is paving the way for a new class of cannabis derived-drugs to treat pain and other conditions. His background and expertise will be valuable as we accelerate growth in the medical marijuana pharmaceutical space and capitalize on the industry's evolution,' says Alex Somjen, President & CEO of Resinco. 'I am pleased to chair Resinco's Advisory Board and work with the team to advance the Second Generation of the Medical cannabis industry,' said Sir Marc Feldmann, Chairman and Founder of ReFormation Pharmaceuticals. 'Through rigorous clinical trials using FDA approved practices, we intend to accelerate ReFormation's development of cannabis treatments triggering stem cell repair, where the medical benefits are based on hard science and government regulation.' About Resinco Capital PartnersResinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical cannabis pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile. Website: www.resincocp.comAbout ReFormation Pharmaceuticals CorpReFormation Pharmaceuticals Corp is a medical cannabis pharmaceutical Company headquartered in Toronto, ON, with its Research and Development team at the University of Oxford. The Company is focused on an innovative approach to repair vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in-class therapeutic. The Company has identified a molecule that primes the body's own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury. The Company's research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is led by world class scientist, CEO and Chief Science Officer, Professor Jagdeep Nanchahal, of the University of Oxford. Website: https://www.reformationpharma.com/ Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking Information: This news release includes certain statements that may be deemed 'forward-looking statements'. The use of any of the words 'anticipate', 'continue', 'estimate', 'expect', 'may', 'will', 'would', 'project', 'should', 'believe' and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com.RESINCO CAPITAL PARTNERS INC.:Company ContactMr. Alexander Somjen, CEO647-362-8998Media ContactTim Gray, Account Director KCSA Strategic CommunicationsPhone: 212.682.6300Email: Resinco@KCSA.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/42665

Click on, or paste the following link into your web browser, to view
the associated documents


06.02.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Resinco Capital Partners Inc.


End of News
DGAP News Service

772895  06.02.2019 

Aktuelle Nachrichten aus der 4investors-Redaktion

25.04.2019 - Siemens Gamesa: News aus den USA
25.04.2019 - Hawesko Holding hält Dividende konstant
25.04.2019 - InTiCa Systems: Autoindustrie wird für 2019 entscheidend
25.04.2019 - home24 legt Zahlen für 2018 vor
25.04.2019 - artec technologies: News aus Katar
25.04.2019 - mVISE: „Die Steigerung der Margen steht bei uns nun absolut im Vordergrund”
25.04.2019 - Wiener Börse: Neue Aktien im global market Segment
25.04.2019 - Wacker Chemie bestätigt Prognose - Ergebnis deutlich unter Druck
25.04.2019 - Norma wird pessimistischer für die Marge
25.04.2019 - Syzygy bestätigt Planungen für 2019


25.04.2019 - Aareal Bank Aktie: Bleibt der wichtige Ausbruch intakt?
25.04.2019 - BASF Aktie: Korrekturbedarf oder nur eine Rallye-Pause?
25.04.2019 - Commerzbank Aktie: Das werden spannende Wochen!
24.04.2019 - Wirecard Aktie - neue Kaufsignale: Die Rallye macht sich selbständig
24.04.2019 - Steinhoff Aktie: Plötzliche Schwankungen - was ist hier los?
24.04.2019 - E.On Aktie: Jetzt wird es kritisch!
24.04.2019 - Aurelius Aktie: Geht die Party in die nächste Runde?
24.04.2019 - TUI Aktie - aufpassen: Kommt jetzt die Erholungsrallye?
24.04.2019 - Paragon Aktie: Kater oder neuer Kaufrausch?
23.04.2019 - Wirecard Aktie: Kleiner Kaufrausch am Nachmittag


25.04.2019 - euromicron Aktie erhält Kaufempfehlung
25.04.2019 - SAP Aktie: Einige neue Kursziele
25.04.2019 - Nokia Aktie: Alles dabei…
25.04.2019 - Deutsche Bank Aktie: Welche Alternativen hat das Unternehmen noch?
25.04.2019 - E.On: Einstelliges Kursziel
25.04.2019 - Deutsche Bank: Kommt ein Aufschwung beim Kurs?
25.04.2019 - Bayer: Ist die Existenz bedroht?
25.04.2019 - Dialog Semiconductor: Kurs nähert sich dem Kursziel an
25.04.2019 - Commerzbank: Nach dem Aus der Fusionspläne – Aktie wird hochgestuft
25.04.2019 - Wirecard: Das ist eine Enttäuschung – Verkaufsempfehlung für die Aktie


25.04.2019 - Indische Börse steigt nach schwächerem Jahresbeginn auf Allzeithoch - Commerzbank Kolumne
25.04.2019 - DAX: Auf der Zielgeraden? - UBS Kolumne
25.04.2019 - Amazon Aktie: Rally erreicht Kurszielbereich - UBS Kolumne
25.04.2019 - DAX mit neuem Jahreshoch: Aufwärtsmodus nachhaltig intakt - Donner & Reuschel Kolumne
24.04.2019 - ifo-Geschäftsklima: Auslandsnachfrage und Politik drücken die Stimmung - Nord LB Kolumne
24.04.2019 - Deutschland: ifo-Geschäftsklimaindex fällt wieder - VP Bank Kolumne
24.04.2019 - DAX: Wird die Luft nun dünn? - UBS Kolumne
24.04.2019 - EuroStoxx 50: Scheitern die Bullen an der 3.500-Punkte-Marke? - UBS Kolumne
24.04.2019 - DAX: Strahlende Frühlingssonne entspricht intaktem Chartmuster - Donner & Reuschel Kolumne
23.04.2019 - DAX: Bullen nicht zu stoppen - UBS Kolumne